Drug intelligence / Profile preview

ciclesonide + fluticasone propionate + salmeterol

Development stage: Unknown
Lead developer: AstraZeneca
Modality: Small Molecules
Administration: Inhalation, Intranasal

Overview

This is a combination therapy consisting of ciclesonide (an inhaled corticosteroid), fluticasone propionate (an inhaled corticosteroid), and salmeterol (a long-acting beta2-adrenergic agonist). Clinical studies have investigated the administration of ciclesonide alongside the fixed combination of fluticasone propionate/salmeterol, particularly examining their effects on cortisol suppression in patients with allergic rhinitis and asthma. The combination has been studied for its efficacy in managing asthma and allergic rhinitis.

Targets

GR (Glucocorticoid receptor)ADRB2 (β2)

Beyond the preview

Go deeper on ciclesonide + fluticasone propionate + salmeterol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ciclesonide + fluticasone propionate + salmeterol.

Explore the full profile